Patents Examined by Jennifer Dunston
-
Patent number: 9782437Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.Type: GrantFiled: July 31, 2014Date of Patent: October 10, 2017Assignee: Sangamo Therapeutics, Inc.Inventors: Michael C. Holmes, Fyodor Urnov
-
Patent number: 9783824Abstract: The teachings herein are generally directed to a method of enhancing the genetic stability of parvovirus vectors. The stability of conventional ss or dsAAV vector constructs can be enhanced, for example, to obtain a concurrent increase in vector titer and purity, as well as an improvement in vector safety, due at least in part to the elimination of stuffer DNA from the AAV vector. The method is broadly applicable to all gene transfer/therapy applications, such as those requiring delivery of foreign DNA containing recombinant gene expression cassettes. Such foreign DNA can range, for example, from about 0.2 up to about 5.2 kb in length. The enhanced vector constructs are highly flexible, user-friendly, and can be easily modified (via routine DNA cloning) and utilized (via standard AAV vector technology) by anyone skilled in the art.Type: GrantFiled: September 1, 2015Date of Patent: October 10, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark A. Kay, Dirk Grimm
-
Patent number: 9758827Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.Type: GrantFiled: June 7, 2010Date of Patent: September 12, 2017Assignee: Comprehensive Biomarker Center GmbHInventors: Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
-
Patent number: 9738890Abstract: The present invention relates to a method based on the use of restriction enzyme digestion and ligation via cleavage sites, thereby to prepare two or more standardized expression cassettes.Type: GrantFiled: March 27, 2013Date of Patent: August 22, 2017Assignee: DSM IP ASSETS B.V.Inventors: Johannes Andries Roubos, Herman Jan Pel, Bernard Meijrink
-
Patent number: 9714453Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.Type: GrantFiled: November 8, 2016Date of Patent: July 25, 2017Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
-
Patent number: 9708608Abstract: The present invention relates to an in vitro or ex vivo method for producing a population of pancreatic beta-cells, comprising the step of inhibiting the expression or the activity of Arx in a population of pancreatic alpha-cells. The present invention also relates to method for inducing the conversion of pancreatic alpha-cells in pancreatic beta-cells in a patient in need thereof.Type: GrantFiled: September 16, 2013Date of Patent: July 18, 2017Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientific (CNRS), Universite Nice Sophia AntipolisInventors: Patrick Collombat, Keith Al-Hasani, Monica Courtney, Nouha Ben-Ohtman, Elisabet Gjernes, Ahmed Mansouri
-
Patent number: 9708668Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.Type: GrantFiled: November 8, 2016Date of Patent: July 18, 2017Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
-
Patent number: 9708670Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.Type: GrantFiled: November 9, 2016Date of Patent: July 18, 2017Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
-
Patent number: 9708669Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, and glycometabolism-related genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.Type: GrantFiled: November 9, 2016Date of Patent: July 18, 2017Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
-
Patent number: 9695442Abstract: Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.Type: GrantFiled: March 4, 2013Date of Patent: July 4, 2017Assignee: Sangamo Therapeutics, Inc.Inventors: Dmitry Guschin, Fyodor Urnov
-
Patent number: 9695396Abstract: A normal regenerated tissue is formed by exposing to radiation a connective tissue or a supporting tissue originating in an organ to thereby form a feeder layer and then transplanting epithelial cells thereon to form a stratified structure. By conveniently and surely providing regenerated tissue by the 3-dimensional culture with the use of a human-origin normal tissue as a base, it is possible to construct systems for assessing effects and side effects of chemicals such as drugs or assessing sensitivities thereof with the use of regenerated tissues as models of corresponding tissues respectively.Type: GrantFiled: October 21, 2013Date of Patent: July 4, 2017Assignee: SHIGEKAZU NAKATSUGAWAInventor: Shigekazu Nakatsugawa
-
Patent number: 9682123Abstract: The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.Type: GrantFiled: December 22, 2014Date of Patent: June 20, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Rudolph L. Leibel, Kazuhisa Watanabe, Wendy K. Chung, Stuart G. Fischer, Charles Leduc, Elizabeth Watson, Maria Laura Cremona
-
Patent number: 9629927Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: September 23, 2013Date of Patent: April 25, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 9580756Abstract: Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and/or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and/or RCC patient is also presented.Type: GrantFiled: March 13, 2014Date of Patent: February 28, 2017Assignee: UNIVERSITY OF NOTRE DAME DU LACInventors: Steven Buechler, Amanda B. Hummon
-
Patent number: 9574226Abstract: Provided herein is a method of using transposition to improve methods of sequencing RNA molecules. Provided herein is a method of tagging nucleic acid duplexes, such as DNA:RNA duplexes or DNA:DNA duplexes. The method includes the steps of providing a transposase and a transposon composition, providing one or more nucleic acid duplexes immobilized on a support, and contacting the transposase and transposon composition with the one or more nucleic acid duplexes under conditions wherein the one or more nucleic acid duplexes and transposon composition undergo a transposition reaction to produce one or more tagged nucleic acid duplexes, wherein the transposon composition comprises a double stranded nucleic acid molecule comprising a transferred strand and a non-transferred strand.Type: GrantFiled: March 6, 2013Date of Patent: February 21, 2017Assignee: Illumina, Inc.Inventors: Niall Anthony Gormley, Louise Fraser, Paula Kokko-Gonzales
-
Patent number: 9567608Abstract: The present invention relates to genetic techniques employing the direct ligatation of an external DNA fragment generated in situ by the same ZFNs that target the genome. ObLiGaRe, i.e., the obligated ligation-gated recombination, is a new method for genetic engineering using custom designed nucleases, and a strategy of site-specific gene insertion utilizing the NHEJ pathway. It applies a similar logic to the one used in unidirectional loxP sites (Oberdoerffer et al., 2003) but maintains all the advantages and flexibility of CDNs.Type: GrantFiled: February 26, 2015Date of Patent: February 14, 2017Assignee: Novartis AGInventors: Yi Yang, Marcello Maresca
-
Patent number: 9546369Abstract: Some aspects of this invention provide nucleic acid constructs for transgene expression. Some aspects of this invention provide multicistronic nucleic acid constructs, for example, comprising an expression cassette encoding a hairpin RNA and a reporter expression cassette. Some aspects of this invention provide nucleic acid constructs comprising two or more self-complementary nucleic acid sequences, for example, hairpin RNA encoding nucleic acid sequences and AAV inverse terminal repeats. Methods for the use of the constructs in therapy and research are also provided.Type: GrantFiled: April 22, 2011Date of Patent: January 17, 2017Assignee: University of MassachusettsInventors: Guangping Gao, Jun Xie
-
Patent number: 9540623Abstract: The present invention relates to a method for increasing double-strand-break induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. More specifically, the present invention concerns the combined use of TALEN or meganucleases with TREX2, especially under the form of single-chain proteins.Type: GrantFiled: July 3, 2012Date of Patent: January 10, 2017Assignee: CELLECTISInventors: George H. Silva, Rachel Macmaster
-
Patent number: 9534248Abstract: The present disclosure encompasses embodiments of nucleic acid minicircle vectors most advantageous for the detection of tumor cells. In particular, the minicircles of the disclosure incorporate a tumor-specific promoter operably linked to a nucleotide sequence desired to be selectively expressed in a tumor cell or a tissue comprising a population of tumor cells. In embodiments of the disclosure, the minicircle vectors comprise a tumor-specific promoter operably linked to a nucleotide sequence encoding a polypeptide useful as a reporter. Accordingly, when expressed by a recipient tumor cell, the reporter may be detectable, thereby providing information such as a visual image of the tumor cell and/or its location in a tissue of the subject human or non-human animal.Type: GrantFiled: September 9, 2014Date of Patent: January 3, 2017Inventors: Sanjiv S. Gambhir, John A. Ronald
-
Patent number: 9523101Abstract: Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles.Type: GrantFiled: July 2, 2014Date of Patent: December 20, 2016Assignee: The Catholic University of AmericaInventor: Venigalla B. Rao